Cantor Fitzgerald Reiterates Overweight on Biogen, Maintains $292 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Eric Schmidt has reiterated an Overweight rating on Biogen (NASDAQ:BIIB) and maintained a price target of $292.
September 09, 2024 | 3:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald's analyst Eric Schmidt has reiterated an Overweight rating on Biogen, maintaining a price target of $292. This suggests confidence in Biogen's stock performance.
The reiteration of an Overweight rating and a maintained price target of $292 by a reputable analyst suggests a positive outlook for Biogen's stock, likely leading to a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100